Heparin is an effective treatment for preventing liver failure after hepatectomy

Table 1 Baseline of patients between two groups

	Before matching			After matching
	Heparin-free group (n = 421)	Heparin group (n = 967)	P value	Heparin-free group (n = 213)	Heparin group (n = 213)	P value
Gender (male/female)	243/178	507/409	0.069	133/80	122/91	0.277
Age (yr)	56.70 ± 14.88	58.10 ± 14.46	0.100	56.00 ± 14.90	57.58 ± 15.58	0.274
Height (cm)	169.20 ± 8.82	168.30 ± 8.57	0.080	170.00 ± 9.09	169.50 ± 9.10	0.551
Weight (kg)	68.10 ± 14.55	66.30 ± 13.28	0.820	69.00 ± 14.36	68.81 ± 14.03	0.870
Malignant tumor (Yes/No)	119 (28.3%)	421 (43.5%)	0.000	55 (25.8%)	74 (34.7%)	0.045
Laparoscopic (Yes/No)	379 (90.0%)	802 (82.9%)	0.001	206 (96.7%)	198 (93%)	0.080
Smoking (Yes/No)	50 (11.9%)	100 (10.3%)	0.397	38 (17.8%)	39 (18.3%)	0.900
Ethnicity (white/not white)	296 (70.3%)	625 (64.6%)	0.040	146 (68.5%)	161 (75.6%)	0.105
Hypertension (Yes/No)	190 (45.1%)	231 (54.9%)	0.787	94 (44.1%)	97 (45.5%)	0.770
PVTT (Yes/No)	21 (5.0%)	37 (3.8%)	0.320	12 (5.6%)	14 (6.6%)	0.686
Diabetes (Yes/No)	5 (1.2%)	61 (6.3%)	0.000	1 (0.5%)	2 (0.9%)	0.562
Cirrhosis (Yes/No)	81 (19.2%)	137 (14.2%)	0.017	56 (26.3%)	50 (23.5%)	0.501
Portal hypertension (Yes/No)	61 (14.5%)	75 (7.8%)	0.000	40 (18.8%)	25 (11.7%)	0.043
COPD (Yes/No)	25 (5.9%)	45 (4.7%)	0.315	14 (6.6%)	10 (4.7%)	0.401
CKD (Yes/No)	39 (9.3%)	40 (4.1%)	0.000	23 (10.8%)	19 (8.9%)	0.516
Transfusion (Yes/No)	83 (19.7%)	92 (9.5%)	0.000	48 (22.5%)	44 (20.7%)	0.638
Laboratory tests
TBIL (mg/mL)	1.1 [0.5, 3.9]	0.9 [0.5, 1.8]	0.002	1.3 [0.5, 4.7]	1.1 [0.6, 3.8]	0.808
AST (U/L)	65 [33, 158]	116 [53, 277]	0.000	68.0 [35.0, 186.5]	89.0 [44.0, 240.0]	0.704
ALT (U/L)	54 [27, 158]	101 [43, 237]	0.000	55.0 [28.0, 168.5]	76.0 [30.0, 210.5]	0.847
LDH (U/L)	263.0 [192.0, 405.0]	272.0 [198.8, 403.5]	0.882	274.0 [199.5, 437.5]	288.0 [201.0, 440.5]	0.487
ALB (g/dL)	3.4 [2.8, 3.8]	3.3 [2.9, 3.7]	0.724	3.4 [2.8, 3.8]	3.2 [2.8, 3.7]	0.639
Cr (mg/dL)	0.9 [0.7, 1.3]	1 [1.0, 1.0]	0.000	0.9 [0.7, 1.4]	1.0 [0.7, 1.4]	0.901
BUN (mg/dL)	16 [11, 28]	14 [11, 20]	0.000	18 [12, 31]	16 [11, 26]	0.629
GFR (mg/dL)	16 [11, 28]	14 [11, 20]	0.000	18 [12, 31]	16 [11, 26]	0.629
WBC (K/μL)	7.3 [5.0, 10.0]	10.0 [7.0, 14.0]	0.000	6.9 [4.7, 9.7]	8.1 [5.0, 12.3]	0.241
PLT (K/μL)	177 [113, 261]	205 [145, 266]	0.001	160.0 [96.0, 235.5]	187.0 [117.5, 245.0]	0.054
INR	1.2 [1.1, 1.6]	1.2 [1.1, 1.4]	0.000	1.2 [1.1, 1.6]	1.3 [1.1, 1.6]	0.408
PT (s)	13.6 [12.1, 18.1]	13.4 [12.2, 15.3]	0.000	13.5 [11.9, 17.8]	14.2 [12.4, 17.3]	0.436
APTT (s)	32 [28.1, 38.7]	29.9 [27.2, 33.9]	0.004	31.6 [28.2, 37.3]	31.0 [27.6, 37.0]	0.202

Variables are shown as “mean (SD)” or “median [IQR]”. Comparisons were made by unpaired student’s test, chi-square test or Mann-Whitney test according to their distribution before propensity score matching (PSM), while paired student’s test, paired chi-square test or Mann-Whitney test are then used after PSM. The bold indicates statistical significance. PVTT: Portal vein tumor thrombus; PSM: Propensity score matching; COPD: Chronic obstructive pulmonary disease; CKD: Chronic kidney disease; RBC: Red blood cell; TBIL: Total bilirubin; AST: Aspartate transaminase; ALT: Alanine transaminase; LDH: Lactate dehydrogenase; ALB: Albumin; Cr: Serum creatinine; BUN: Blood urea nitrogen; GFR: Glomerular filtration rate; WBC: White blood cell; INR: International normalized ratio; PLT: Platelets; PT: Prothrombin time; APTT: Activated partial thromboplastin time.